Month-to-month variability of lipids, lipoproteins, and apolipoproteins and the impact of acute infection in adolescents


      Objective: To assess month-to-month variability of total cholesterol, triglycerides, high-density lipoprotein–cholesterol (HDL-C), calculated low-density lipoprotein–cholesterol (LDL-C), apolipoprotein A1, apolipoprotein B, and lipoprotein (a), as well as factors that could influence variability, including recent acute infection in an adolescent population. Methods: Sixty-three high school students had fasting lipids and lipoproteins measured at 4 separate times during the school year and another venipuncture 3 to 7 days after recovery from an acute infection. Erythrocyte sedimentation rate was also measured. Coefficients of variation were calculated for each study variable. The influence of recent infection on variability was assessed. Results: The 50th and 95th percentiles, respectively, for the coefficient of variation for each variable were as follows: total cholesterol, 7.3% and 13.6%; triglycerides, 22% and 47.3%; HDL-C, 7.9% and 16.8%; LDL-C, 12.1% and 25%; apolipoprotein A1, 6.3% and 15.2%; apolipoprotein B, 9.5% and 17.2%; and lipoprotein (a), 19.3% and 40%. Recent infection significantly lowered HDL-C (4 mg/dL; P < .0001) and apolipoprotein A1 (7 mg/dL; P < .005). Conclusions: Clinicians evaluating lipids and lipoproteins serially should expect significant visit-to-visit variation in triglycerides and calculated LDL-C values. Assessment of HDL-C and apolipoprotein A1 should not be done within 2 weeks of an acute infection. Apolipoproteins B and A1 have slightly less variability than their respective lipoprotein cholesterol values (LDL-C and HDL-C). (J Pediatr 1998;133:242-6)


      ApoA1 ( Apolipoprotein A1), ApoB ( Apolipoprotein B), HDL ( High-density lipoprotein), HDL-C ( High-density lipoprotein–cholesterol), LDL ( Low-density lipoprotein), LDL-C ( Low-density lipoprotein–cholesterol), Lp(a) ( Lipoprotein (a))
      To read this article in full you will need to make a payment


      1. Pediatrics. 1992; 89: 525-584
        • Fredrickson DS
        • Goldstein JL
        • Brown MS.
        The familial hyperlipoproteinemias.
        in: 4th ed. The metabolic basis of inherited disease. : McGraw-Hill International Book Co, New York1978: 604-655
        • Gidding SS.
        The rationale for lowering serum cholesterol levels in American children.
        Am J Dis Child. 1993; 147: 386-392
        • Srinivasan SR
        • Berenson GS.
        Childhood lipoprotein profiles and implications for adult coronary disease.
        Am J Med Sci. 1995; 310: s62-s67
        • Rader DJ
        • Hoeg JM
        • Bremer Jr., B
        Quantitation of plasma apolipoprotein in the primary and secondary prevention of coronary artery disease.
        Ann Intern Med. 1994; 120: 1012-1025
        • Friedewald WT
        • Levy RI
        • Fredrickson DS.
        Estimation of the concentration of low density lipoprotein cholesterol in plasma without use of the preparation ultracentrifuge.
        Clin Chem. 1972; 18: 499-502
        • Steiner PM
        • Friedel J
        • Bremner WF
        • Stein EA
        Standardization of micromethods for plasma cholesterol, triglyceride and HDL-cholesterol with the Lipid Clinics’ methodology [abstract].
        J Clin Chem. 1981; 19: 850
        • Myers GL
        • Cooper GR
        • Winn CL
        • Smith SJ
        The Centers for Disease Control–National Heart, Lung, and Blood Institute Lipid Standardization Program: an approach to accurate and precise lipid measurements.
        Clin Lab Med. 1989; 9: 105-135
        • Warnick GR
        • Benderson J
        • Albers JJ
        Dextran sulfate–Mg++ precipitation procedure for quantitation of high-density lipoprotein cholesterol.
        Clin Chem. 1982; 28: 1379-1388
        • Albers JJ
        • Marcovina SM
        • Kennedy H.
        International Federation of Clinical Chemistry standardization project for measurements of apolipoproteins A-I and B. II. Evaluation and selection and candidate reference materials.
        Clin Chem. 1992; 38: 658-662
        • Stein EA
        • Kumbla L
        • Miller J
        • Srivastiva L
        • Kashyap M.
        Development and evaluation of a competitive ELISA for Lp(a).
        Clin Chem. 1992; 38 ([abstract]): 1067
        • Bookstein LC
        • Gidding SS
        • Donovan M
        • Smith FA.
        Day-to-day variability of serum cholesterol, triglyceride, and high-density lipoprotein cholesterol levels: impact on the assessment of risk according to the National Cholesterol Education Program guidelines.
        Arch Intern Med. 1990; 150: 1653-1657
        • Benuck I
        • Gidding SS
        • Dononvon M.
        Year-to-year variability of cholesterol levels in a pediatric practice.
        Arch Pediatr Adolesc Med. 1995; 149: 292-296
        • Gillman MW
        • Cupples LA
        • Moore LL
        • Ellison RC
        Impact of within-person variability on identifying children with hypercholesterolemia: Framingham Children’s Study.
        J Pediatr. 1992; 121: 342-347
        • National Cholesterol Education Program
        Current status of blood cholesterol measurement in clinical laboratories in the United States: report from the laboratory standardization panel.
        Clin Chem. 1988; 34: 193-201
        • Kafonek SD
        • Derby CA
        • Bachorik PS.
        Biological variability of lipoproteins and apolipoproteins in patients referred to a lipid clinic.
        Clin Chem. 1992; 38: 864-872
        • Abate N
        • Vega GL
        • Grundy SM.
        Variability in cholesterol content and physical properties of lipoproteins containing apolipoprotein-100.
        Atherosclerosis. 1993; 104: 159-171
        • Ramos A
        • Alvarez C.
        Lipids, lipoproteins, and apoproteins in serum during infection.
        Clin Chem. 1986; 32: 142-145
        • Page IH
        • Lewis LA.
        A long-time study of the blood lipids of two students of atherosclerosis.
        Circulation. 1969; 40: 915-918
        • Hyman DJ
        • Barrett DC
        • Fortman SP.
        Effect of minor illness on serum cholesterol level.
        Am J Prev Med. 1992; 8: 100-103
        • Silverman DI
        • Ginsburg GS
        • Pasternak RC.
        High-density lipoprotein subfractions.
        Am J Med. 1993; 94: 636-645
        • Srinivasan SR
        • Dahlen GH
        • Jarpa RA
        • Webber LS
        • Berenson GS.
        Racial (black-white) differences in serum lipoprotein (a) distribution and its relation to parental myocardial infarction in children: the Bogalusa Heart Study.
        Circulation. 1991; 84: 160-167
        • Scanu AM.
        Lipoprotein (a): a genetic risk factor for premature coronary artery disease.
        JAMA. 1992; 267: 3326-3330
        • Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults
        National Cholesterol Education Program Second Report of the Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II).
        (NIH publication No. 93-3095.)in: : National Institutes of Health, Bethesda (MD)1993: I1-I8
        • Freedman DS
        • Srinivasan SR
        • Shear CL
        • Franklin FA
        • Webber LS
        • Berenson GS.
        The relation of apolipoproteins A-1 and B in children to parental myocardial infarction.
        N Engl J Med. 1986; 315: 721-726
        • Sniderman A
        • Shapiro S
        • Marple D
        • Skinner B
        • Terry B
        • Kwiterovich Jr., PO
        Association of coronary atherosclerosis with hyperapobetalipoproteinemia (increased protein but normal cholesterol levels in human plasma low density lipoproteins).
        Proc Natl Acad Sci USA. 1980; 77: 605-608
        • Cortner JA
        • Coates PM
        • Gallagher PR.
        Prevalence and expression of familial combined hyperlipidemia in childhood.
        J Pediatr. 1990; 116: 514-519
        • Lamarche B
        • Moorjani S
        • Lupien PJ
        • Cantin B
        • Bernard PM
        • Dagenais GR
        • et al.
        Apolipoprotein A-I and B levels and the risk of ischemic heart disease during a five-year follow-up of men in the Quebec Cardiovascular Study.
        Circulation. 1996; 94: 272-278